3-furan-2-yl-[1,2,4]thiadiazol-5-ylamine | 138588-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-furan-2-yl-[1,2,4]thiadiazol-5-ylamine
• 英文别名: 3-(Furan-2-yl)-1,2,4-thiadiazol-5-amine
• CAS: 138588-30-4
• 化学式: C₆H₅N₃OS
• 分子量: 167.191
• InChiKey: PTMHTJZFLJCDHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  93.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Substituted 5-amino-1,2,4-thiadiazoles with pharmaceutical activity
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0455356A1

  公开（公告）日：1991-11-06

  Pharmaceutical compounds of the following formula are described: in which R¹ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, hydroxy-C₁₋₄ alkyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋₄ alkyl or a heterocycle selected from: where R³ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, nitro, halo, cyano, trifluoromethyl, carboxyl or -CONH₂, and R⁴ is C₁₋₄ alkyl; and R² is hydrogen, C₁₋₄ alkyl, phenyl or thienyl substituted with a carboxyl or C₁₋₄ alkoxy-carbonyl group, an acyl group of the formula R⁵CO- where R⁵ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, halo C₁₋₄ alkyl, C₁₋₄ alkoxy, halo-C₁₋₄ alkoxy, phenyl, phenyl-C₁₋₄ alkyl, -NHC₁₋₄ alkyl, -NH phenyl or where R⁶ is C₁₋₄ alkyl, or a group of the formula -CH=C(COC₁₋₄ alkoxy)₂; or a salt thereof.

  以下是描述的具有以下结构的药物化合物： 其中R¹为氢、C₁₋₄烷基、C₁₋₄烷氧基-C₁₋₄烷基、羟基-C₁₋₄烷基、可选择取代的苯基、可选择取代的苯基-C₁₋₄烷基或从以下选取的杂环： 其中R³为氢、C₁₋₄烷基、C₁₋₄烷氧基、硝基、卤素、氰基、三氟甲基、羧基或-CONH₂，R⁴为C₁₋₄烷基；而R²为氢、C₁₋₄烷基、苯基或经羧基或C₁₋₄烷氧基羰基取代的噻吩基，具有R⁵CO-式的酰基，其中R⁵为氢、C₁₋₄烷基、C₁₋₄烷氧基-C₁₋₄烷基、卤素C₁₋₄烷基、C₁₋₄烷氧基、卤素-C₁₋₄烷氧基、苯基、苯基-C₁₋₄烷基、-NHC₁₋₄烷基、-NH苯基或 其中R⁶为C₁₋₄烷基，或具有-CH=C(COC₁₋₄烷氧基)₂式的基团；或其盐。
• LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV
  申请人：GRAFFINITY PHARMACEUTICALS GMBH

  公开号：US20160009760A1

  公开（公告）日：2016-01-14

  The present invention relates to the use, for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) L-(Sp) v -Ar 1 —Am—Ar 2 (I) wherein L, SP, Ar 1 , AM, Ar 2 and v are defined herein.

  本发明涉及使用含有配体取代基质来亲和纯化抗体或抗体片段，所述基质包括支持材料和至少一个与支持材料共价结合的配体，所述配体由式(I)所表示：L-(SP)v-Ar1—AM—Ar2(I)，其中L、SP、Ar1、AM、Ar2和v在此处有定义。
• US9745339B2
  申请人：——

  公开号：US9745339B2

  公开（公告）日：2017-08-29
• [EN] LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV<br/>[FR] LIGANDS POUR ANTICORPS ET PURIFICATION DE PROTÉINE DE FUSION À FRAGMENT CONSTANT PAR CHROMATOGRAPHIE D'AFFINITÉ IV
  申请人：GRAFFINITY PHARMACEUTICALS GMBH

  公开号：WO2013117707A1

  公开（公告）日：2013-08-15

  The present invention relates to the use, for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) L-(Sp)v-Ar1-Am-Ar2 wherein L is the linking point on the support material to which the ligand is attached; Sp is a spacer group; v is 0 or 1; Am is an amide group -NR1-C(O)-, and wherein either NR1 is attached to Ar1 and -C(O)- is attached to Ar2, or -C(O)- is attached to Ar1 and NR1 is attached to Ar2; and R1 is hydrogen or C1 to C4 alkyl, more preferably hydrogen or methyl; and most preferably hydrogen; Ar1 is a 5-, 6- or 7-membered mononuclear aromatic ring or partially saturated aromatic ring connected to Sp or L via a chemical bond and which is optionally furthermore (a) attached to a further 5- or 6-membered mononuclear aromatic ring via a chemical bond; or (b) fused to a mononuclear or binuclear aromatic ring as part of a multinuclear ring system wherein Ar1 is directly connected to Am via a chemical bond present on the said 5-, 6- or 7- membered aromatic ring constituting Ar1, or indirectly via a chemical bond which is either present at the further 5- or 6-membered aromatic ring attached to Ar1, or on the further 5- or 6- membered aromatic ring fused to Ar1; and wherein Ar1 is either not further substituted or attached to at least one substituent selected from C1 to C4 alkyl; C3 and C4 cycloalkyl; C2 to C4 alkenyl;; C2 to C4 alkynyl; a halogen; C1 to C4 haloalkyl;;; hydroxyl-substituted C1 to C4 alkyl; C1 to C4 alkoxy; hydroxyl-substituted C1 to C4 alkoxy; halogen-substituted C1 to C4 alkoxy; C1 to C4 alkylamino; C1 to C4 alkylthio; -NO2; =O; =S; =NH; -OH?; and combinations thereof; Ar2 is a 5- or 6-membered mononuclear aromatic ring which is unsubstituted, or via a chemical bond attached to at least one substituent selected from C1 to C6 alkyl; C3 to C6 cycloalkyl; C2 to C6 alkenyl; C5 and C6 cycloalkenyl; C2 to C6 alkynyl; a halogen; C1 to C6 haloalkyl; hydroxyl-substituted C1 to C6 alkyl; C1 to C6 alkoxy; hydroxyl-substituted C1 to C6 alkoxy; halogen-substituted C1 to C6 alkoxy; C1 to C6 alkylamino; C1 to C6 alkylthio; carbamoyl; methylenedioxy; ethylenedioxy; -OH; SH; a 5- or 6-membered mononuclear aromatic ring; and combinations thereof; and wherein Ar2 optionally, further to the substituents to which it may be attached via a chemical bond as cited above, is fused to a 5- or 6-membered mononuclear aromatic ring as part of a multinuclear ring system.